Dedicated to Advancing Liver Cancer Research

PHOCUS is a Phase 3 liver cancer trial.
Is this investigational trial right for you?

Print this Fact sheet to share with your physician.



about PHOCUS

This research study is for people with advanced liver cancer (hepatocellular carcinoma or HCC) who have never received systemic medicine (affecting the entire body) for advanced liver cancer.  green-link-arrow.png


your eligibility

Is your liver cancer in an advanced stage? Are you able to take care of daily activities by yourself?  green-link-arrow.png


a trial center

Learn more about your options and how you can get started today. Multiple locations are available in the following regions (US, Canada, Europe, Asia, Australia).  green-link-arrow.png

The PHOCUS Trial

The PHOCUS Trial is evaluating an investigational drug called Pexa-Vec (JX-594), to determine if it can slow the progression of advanced liver cancer (also called hepatocellular carcinoma or HCC) and improve quality of life.

In pre-clinical models, Pexa-Vec targets cancer in three ways:

  • Target and kill cancer cells
  • Cut off the blood supply to tumors to stop their growth
  • Activate the body's own immune system to fight the cancer

What is the Investigational Therapy?

The investigational therapy, Pexa-Vec (JX-594), is an oncolytic immunotherapy that is being evaluated to determine if it may be effective in targeting and destroying liver tumors in people who are eligible to be treated with an approved therapy called sorafenib (Nexavar®).

All study participants will receive the standard of care for advanced liver cancer – sorafenib (Nexavar®) at no cost (provided by the sponsor of the study). Sorafenib is the only approved systemic medicine (affecting the entire body) for advanced liver cancer.